Back to News
Market Impact: 0.6

Equities stall as early enthusiasm ebbs; Amazon, Apple earnings due

AMZNAAPLMSFTNVDATRIMETAAVGOSPYDIAQQQ
Corporate EarningsMarket Technicals & FlowsEconomic DataInflationTax & TariffsTrade Policy & Supply ChainArtificial IntelligenceTechnology & Innovation
Equities stall as early enthusiasm ebbs; Amazon, Apple earnings due

US equities closed lower Thursday, reversing early session gains, despite strong earnings reports from Microsoft, which briefly surpassed a $4 trillion market cap, and Meta Platforms, which surged 11.3% to a record high on AI-driven ad growth. Market sentiment was dampened by a 3.1% decline in the semiconductor index, weakness in drug stocks following White House pressure, and concerns over June's inflation pickup driven by tariffs. Post-market, Amazon shares shed 2.6% after reporting quarterly results, further highlighting the mixed corporate landscape as 80.8% of S&P 500 companies have beaten expectations this earnings season.

Analysis

The U.S. equity market exhibited significant divergence and a loss of momentum, closing lower despite strong individual corporate performances. Early session gains, which saw the S&P 500 rise by as much as 1% and the Nasdaq by 1.5%, were fully erased, signaling investor caution ahead of key earnings and economic data. A clear 'haves and have-nots' dynamic emerged within the technology sector; Microsoft (MSFT) gained 3.5% on strong earnings to briefly touch a $4 trillion market capitalization, while Meta Platforms (META) surged 11.3% to a record high, driven by an AI-powered ad business. In stark contrast, the semiconductor sector faced a significant sell-off, with the PHLX semiconductor index falling 3.1%, its largest daily percentage drop since April 16, dragged down by names like Broadcom (-2.9%) and Nvidia (-0.8%). Macroeconomic pressures are mounting, with Commerce Department data indicating a pickup in June inflation attributed to tariffs. This, combined with political headwinds hitting the pharmaceutical sector—evidenced by the NYSE Arca pharmaceutical index's 2.9% slump following White House pressure on drug pricing—contributed to the broader market weakness. Despite the negative close, with declining issues outnumbering advancers on both the NYSE and Nasdaq, all three major indices secured their third consecutive monthly gain.